Front. Immunol.
Frontiers in Immunology
Front. Immunol.
1664-3224
Frontiers Media S.A.
10.3389/fimmu.2024.1527232
Immunology
Correction
Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
Fu
Chenghao
1
2
†
Du
Haonan
1
†
Wang
Qiang
3
†
Zhu
Weiyou
1
Bian
Guangli
4
Zhong
Zhujuan
5
Wang
Yuheng
2
Cao
Lei
6
*
1
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
2
Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
3
Department of Thoracic Surgery, Taizhou Fourth People’s Hospital, Taizhou, Jiangsu, China
4
Department of Radiology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, China
5
Department of Pathology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, China
6
Department of Oncology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, China
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Lei Cao, BrawnyM80@163.com
†These authors have contributed equally to this work
26
11
2024
2024
15
1527232
13
11
2024
14
11
2024
Copyright © 2024 Fu, Du, Wang, Zhu, Bian, Zhong, Wang and Cao
2024
Fu, Du, Wang, Zhu, Bian, Zhong, Wang and Cao
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib By Fu C, Du H, Wang Q, Zhu W, Bian G, Zhong Z, Wang Y and Cao L (2024). Front. Immunol. 15:1452195. doi: 10.3389/fimmu.2024.1452195
tail effect
immunotherapy
cancer therapy
PSC
ICI
Sintilimab
section-in-acceptance
Cancer Immunity and Immunotherapy
In the published article, there was an error in affiliations 4, 5, 6. Instead of “The First People’s Hospital of Suqian”, it should be “The Affiliated Suqian First People’s Hospital of Nanjing Medical University”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.